What is Slimfast?
Slimfast is used together with a reduced-calorie diet to help you lose weight and to help keep the lost weight from returning. It is also used in overweight people who may also have diabetes, high blood pressure, high cholesterol, or heart disease.
Slimfast works by keeping your intestines from absorbing some of the fats from the food that you eat. The undigested fat goes out of your body in your bowel movements.
Slimfast is available both over-the-counter (OTC) and with your doctor's prescription.
Slimfast is an anti-obesity agent. Slimfast is used to help obese people lose weight and keep this weight off. It does not suppress your appetite or act on the brain. It works in the digestive system, where it blocks about one-third of the fat in the food you eat from being digested. Since fat contains more calories than other components in foods, cutting the fat that is digested by your body is an effective way to limit daily calories and lose weight. It is a potent, specific and long-acting inhibitor of gastrointestinal lipases. The inactivated enzyme is thus unavailable to hydrolyse dietary fat, and this allows about 30% of the fat eaten in the meal to pass through the gut undigested. Your body therefore, cannot use this dietary fat as a source of energy and convert it to fat tissue. This will help you reduce your weight.
Slimfast is indicated in the treatment of obesity in conjunction with a mildly hypocaloric diet.
How should I use Slimfast?
Use Slimfast as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- An extra patient leaflet is available with Slimfast. Talk to your pharmacist if you have questions about this information.
- Take Slimfast by mouth with or up to 1 hour after each main meal that contains fat (up to 3 per day).
- If a meal is missed or contains no fat, do not take a dose of Slimfast.
- You should take a multivitamin supplement containing vitamins A, D, E, and K to ensure good nutrition. The supplement should be taken at least 2 hours before or after you take Slimfast, such as at bedtime.
- If you also take a thyroid hormone (eg, levothyroxine), do not take it within 4 hours before or after taking Slimfast. Check with your doctor if you have questions.
- If you also take cyclosporine, do not take it within 3 hours before or after taking Slimfast. Check with your doctor if you have questions.
- If you miss a dose of Slimfast, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Slimfast.
Uses of Slimfast in details
Slimfast is used for weight loss along with an exercise and diet regimen. It is also prescribed by doctors to overweight people who may be suffering from high blood pressure, high cholesterol, diabetes and heart patients. It is also used to stop weight gain after weight reduction.
Slimfast is a drug designed to treat obesity. Its primary function is preventing the absorption of fats from the human diet, thereby reducing caloric intake. Slimfast works by inhibiting pancreatic lipase, an enzyme that breaks down triglycerides in the intestine. Without this enzyme, triglycerides from the diet are prevented from being hydrolyzed into absorbable free fatty acids and are excreted undigested.
Usual Adult Dose for Obesity
120 mg orally three times a day with each main meal containing fat. The dose may be taken during the meal or within 1 hour of completing the meal.
Usual Pediatric Dose for Obesity
12 years or older:
120 mg orally three times a day with each main meal containing fat. The dose may be taken during the meal or within 1 hour of completing the meal.
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
If a meal is occasionally missed or contains no fat, the dose of Slimfast may be skipped.
The use of Slimfast is contraindicated in patients with chronic malabsorption syndrome or cholestasis. Organic causes of obesity, such as hypothyroidism, should be excluded before prescribing Slimfast.
Gastrointestinal effects may increase when Slimfast is taken with any one meal high in fat.
Slimfast may reduce the absorption of some fat-soluble vitamins and beta-carotene. In addition, levels of vitamin D and beta-carotene may often be low in obese patients. To ensure adequate nutrition, supplementation with a multivitamin is recommended. The supplement should be taken at least two hours before or after the administration of Slimfast, such as at bedtime.
Elevated levels of urinary oxalate may develop in some patients treated with Slimfast. Cases of oxalate nephrolithiasis and oxalate nephropathy with renal failure have been reported. In patients at risk for renal impairment, it is recommended that renal function be monitored. Caution should be exercised when prescribing Slimfast to patients with a history of hyperoxaluria or calcium oxalate nephrolithiasis.
Improved control of diabetes may accompany the weight-loss seen with Slimfast. A dosage reduction of oral hypoglycemics or insulin may be needed.
There is an increased risk of cholelithiasis with substantial weight loss.
Data not available
Slimfast reduces the absorption of some fat-soluble vitamins, therefore, multivitamin supplementation is necessary. The multivitamin should be administered once a day, at least 2 hours before or after Slimfast is taken.
The patient should be started on a nutritionally balanced, reduced-calorie diet that contains approximately 30% of calories from fat. The daily intake of fat, carbohydrate, and protein should be distributed over three main meals.
Dosages greater than 120 mg orally three times a day have not been shown to provide additional benefit.
Transplant Rejection Medicines (e.g., Ciclosporin): Taking Slimfast and ciclosporin at the same time may decrease the absorption of ciclosporin making it less effective. If the patient take ciclosporin, the patient should check with the doctor before taking Slimfast. The doctor may recommend the patient to take ciclosporin at least three hours before or after Slimfast in order to avoid the interaction.
Medicines Used to Treat Irregular Heart Beat (e.g. Amiodarone): Slimfast may interfere with the absorption of this medicine making it less effective.
Anticoagulants or Medicines that Prevent Blood Clots (e.g., Warfarin): Slimfast can affect the level of vitamin K in the body, which affects the way the patient respond to warfarin. The doctor may need to monitor the patient more closely and adjust the warfarin dosage as necessary if the patient are taking these medicines at the same time.
Diabetes Medicines: Often, when people with diabetes lose weight, their diabetes medicines need to be adjusted (typically with lower dosages). Make sure that the doctor is aware of the patient's plan for weight loss with Slimfast, as the patient may need to be monitored more closely. As the patient lose weight, the doctor may need to decrease the dose of diabetes medicines accordingly.
Thyroid Medicines (e.g., Liothyronine, levothyroxine): Weight loss can affect how much thyroid medicine the patient need. If the patient take thyroid medicines, make sure to tell the doctor about the weight loss plans. The doctor may choose to monitor the patient more closely while taking Slimfast, adjusting the dose of thyroid medicines if necessary. Take levothyroxine and Slimfast at least 4 hours apart.
Vitamins: Slimfast can decrease the absorption of certain vitamins from the diet, possibly leading to a vitamin deficiency. In particular, this interaction affects fat-soluble vitamins, such as vitamins A, D, E, K and beta-carotene.
Antiepileptic Medicines (e.g., Valproate, lamotrigine): Slimfast may decrease the absorption of antiepileptic medicines which may lead to convulsions. Inform the doctor if there are changes in the frequency and/or severity of convulsions.
Make sure to tell the doctor about all the medicines the patient takes, including prescription and non-prescription medicines, vitamins and herbal supplements.
Slimfast side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in patients.
Commonly Observed (based on first year and second year data)
Gastrointestinal (GI) symptoms were the most commonly observed treatment-emergent adverse events associated with the use of Slimfast in the seven double-blind, placebo-controlled clinical trials and are primarily a manifestation of the mechanism of action. (Commonly observed is defined as an incidence of ≥5% and an incidence in the Slimfast 120 mg group that is at least twice that of placebo.)
In general, the first occurrence of these events was within 3 months of starting therapy. Overall, approximately 50% of all episodes of GI adverse events associated with Slimfast treatment lasted for less than 1 week, and a majority lasted for no more than 4 weeks. However, GI adverse events may occur in some individuals over a period of 6 months or longer.
Discontinuation of Treatment
In controlled clinical trials, 8.8% of patients treated with Slimfast discontinued treatment due to adverse events, compared with 5.0% of placebo-treated patients. For Slimfast, the most common adverse events resulting in discontinuation of treatment were gastrointestinal.
Other Adverse Clinical Events
The following table lists other treatment-emergent adverse events from seven multicenter, double-blind, placebo-controlled clinical trials that occurred at a frequency of ≥2% among patients treated with Slimfast 120 mg three times a day and with an incidence that was greater than placebo during year 1 and year 2, regardless of relationship to study medication.
In the 4-year XENDOS study, the general pattern of adverse events was similar to that reported for the 1- and 2-year studies with the total incidence of gastrointestinal-related adverse events occurring in year 1 decreasing each year over the 4-year period.
In clinical trials in obese diabetic patients, hypoglycemia and abdominal distension were also observed.
In clinical trials with Slimfast in adolescent patients ages 12 to 16 years, the profile of adverse reactions was generally similar to that observed in adults.
The following adverse reactions have been identified during postapproval use of Slimfast. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to Slimfast exposure.
- Rare cases of increase in transaminases and in alkaline phosphatase and hepatitis that may be serious have been reported. There have been reports of hepatic failure observed with the use of Slimfast in postmarketing surveillance, with some of these cases resulting in liver transplant or death.
- Cases of reduced concentrations of cyclosporine have been reported when cyclosporine was co-administered with Slimfast.
- Rare cases of hypersensitivity have been reported with the use of Slimfast. Signs and symptoms have included pruritus, rash, urticaria, angioedema, bronchospasm and anaphylaxis. Very rare cases of bullous eruption have been reported.
- Rare cases of leukocytoclastic vasculitis have been reported. Clinical signs include palpable purpura, maculopapular lesions, or bullous eruption.
- Reports of decreased prothrombin, increased INR and unbalanced anticoagulant treatment resulting in change of hemostatic parameters have been reported in patients treated concomitantly with Slimfast and anticoagulants.
- Hypothyroidism has been reported in patients treated concomitantly with Slimfast and levothyroxine.
- Acute oxalate nephropathy after treatment with Slimfast has been reported in patients with or at risk for renal disease.
- Pancreatitis has been reported with the use of Slimfast in postmarketing surveillance. No causal relationship or physiopathological mechanism between pancreatitis and obesity therapy has been definitively established.
- Lower gastrointestinal bleeding has been reported in patients treated with Slimfast. Most reports are nonserious; severe or persistent cases should be investigated further.
- Convulsions have been reported in patients treated concomitantly with Slimfast and antiepileptic drugs.
Hypersensitivity to Slimfast or to any of the excipients of Slimfast.
Chronic malabsorption syndrome; cholestasis.
Use in lactation: It is not known whether Slimfast is secreted into human milk therefore, it is contraindicated during breastfeeding.
Slimfast has been assigned to pregnancy category X by the FDA. High-dose animal studies have failed to reveal evidence of embryotoxicity or teratogenicity. There are no controlled data in human pregnancy. Since weight loss offers no potential benefit to a pregnant woman and may result in fetal harm, Slimfast is contraindicated during pregnancy. If Slimfast is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard of maternal weight loss to the fetus.
Single doses of Slimfast 800 mg and multiple doses of up to 400 mg 3 times daily for 15 days have been studied in normal weight and obese subjects without significant adverse findings. In addition, doses of 240 mg 3 times daily have been administered to obese patients for 6 months without significant increase of adverse findings.
Slimfast overdose cases received during post-marketing reported either no adverse events or adverse events that are similar to those reported with recommended dose.
Should a significant overdose of Slimfast occur, it is recommended that the patient be observed for 24 hrs. Based on human and animal studies, any systemic effects attributable to the lipase-inhibiting properties of Slimfast should be rapidly reversible.
Concomitant Drug and Vitamin Use
Data from a Slimfast and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when Slimfast was coadministered with cyclosporine. Therefore, Slimfast and cyclosporine should not be simultaneously coadministered. To reduce the chance of a drug-drug interaction, cyclosporine should be taken at least 3 hours before or after Slimfast in patients taking both drugs. In addition, in those patients whose cyclosporine levels are being measured, more frequent monitoring should be considered.
Patients should be strongly encouraged to take a multivitamin supplement that contains fat-soluble vitamins to ensure adequate nutrition because Slimfast has been shown to reduce the absorption of some fat-soluble vitamins and beta-carotene. In addition, the levels of vitamin D and beta-carotene may be low in obese patients compared with non-obese subjects. The supplement should be taken once a day at least 2 hours before or after the administration of Slimfast, such as at bedtime.
illustrates the percentage of adult patients on Slimfast and placebo who developed a low vitamin level on two or more consecutive visits during 1 and 2 years of therapy in studies in which patients were not previously receiving vitamin supplementation.
illustrates the percentage of adolescent patients on Slimfast and placebo who developed a low vitamin level on two or more consecutive visits during the 1-year study.
Weight-loss may affect glycemic control in patients with diabetes mellitus. A reduction in dose of oral hypoglycemic medication (eg, sulfonylureas) or insulin may be required in some patients.
There have been rare postmarketing reports of severe liver injury with hepatocellular necrosis or acute hepatic failure in patients treated with Slimfast, with some of these cases resulting in liver transplant or death. Patients should be instructed to report any symptoms of hepatic dysfunction (anorexia, pruritus, jaundice, dark urine, light-colored stools, or right upper quadrant pain) while taking Slimfast. When these symptoms occur, Slimfast and other suspect medications should be discontinued immediately and liver function tests and ALT and AST levels obtained.
Increases in Urinary Oxalate
Some patients may develop increased levels of urinary oxalate following treatment with Slimfast. Cases of oxalate nephrolithiasis and oxalate nephropathy with renal failure have been reported. Monitor renal function when prescribing Slimfast to patients at risk for renal impairment and use with caution in those with a history of hyperoxaluria or calcium oxalate nephrolithiasis.
Substantial weight loss can increase the risk of cholelithiasis. In a clinical trial of Slimfast for the prevention of type 2 diabetes, the rates of cholelithiasis as an adverse event were 2.9% (47/1649) for patients randomized to Slimfast and 1.8% (30/1655) for patients randomized to placebo.
Organic causes of obesity (eg, hypothyroidism) should be excluded before prescribing Slimfast.
Patients should be advised to adhere to dietary guidelines. Gastrointestinal events may increase when Slimfast is taken with a diet high in fat (>30% total daily calories from fat). The daily intake of fat should be distributed over three main meals. If Slimfast is taken with any one meal very high in fat, the possibility of gastrointestinal effects increases.
Active ingredient matches for Slimfast:
Orlistat in Bangladesh, India.
|Unit description / dosage (Manufacturer)||Price, USD|
|SlimFast - 30 Capsule||$ 24.95|
|SlimFast - 90 Capsule||$ 54.95|
|SLIMFAST cap 60 mg x 10's (Intra (Intra Life))||$ 3.97|
|SLIMFAST cap 120 mg x 10's (Intra (Intra Life))||$ 7.14|
List of Slimfast substitutes (brand and generic names):
|SLIMREX cap 120 mg x 10's (Pax Healthcare)||$ 8.41|
|Symfona (Chile, Peru)|
|Capsule; Oral; Ginkgo Biloba Extract 60 mg (Medichemie)|
|Capsule; Oral; Orlistat 120 mg (Medichemie)|
|Troyslim 120mg CAP / 10 (Troikaa Pharmaceuticals Ltd.)||$ 6.05|
|Troyslim 120 mg Capsule (Troikaa Pharmaceuticals Ltd.)||$ 0.67|
|TROYSLIM 120MG CAPSULE 1 strip / 10 capsules each (Troikaa Pharmaceuticals Ltd.)||$ 7.14|
|TROYSLIM cap 120 mg x 10's (Troikaa Pharmaceuticals Ltd.)||$ 6.05|
|ULTISLIM 120 MG TABLET 1 strip / 10 tablets each (Akumentis Healthcare Ltd)||$ 6.17|
|ULTISLIM 60 MG TABLET 1 strip / 10 tablets each (Akumentis Healthcare Ltd)||$ 3.97|
|Ultislim 120mg Tablet (Akumentis Healthcare Ltd)||$ 0.62|
|Ultislim 60mg Tablet (Akumentis Healthcare Ltd)||$ 0.40|
|Capsule; Oral; Orlistat 120 mg|
|Capsule; Oral; Orlistat 120 mg|
|Venustat® Cap (120 Mg)|
|Viplena (Chile, Ecuador, Peru)|
|Capsule; Oral; Orlistat 120 mg (K2 pharmacare)|
|Viplena 120 (Vietnam)|
|Viplena 120 120 mg x 2 Blister x 10 Tablet|
|Vyfat 120mg CAP / 10 (Intas Pharmaceuticals Ltd.)||$ 6.11|
|120 mg x 10's (Intas Pharmaceuticals Ltd.)||$ 5.56|
|Vyfat 120 mg Capsule (Intas Pharmaceuticals Ltd.)||$ 0.61|
|Vyfat 60 mg Capsule (Intas Pharmaceuticals Ltd.)||$ 0.32|
|VYFAT 120 MG CAPSULE 1 strip / 10 capsules each (Intas Pharmaceuticals Ltd.)||$ 7.62|
|VYFAT cap 120 mg x 10's (Intas Pharmaceuticals Ltd.)||$ 6.11|
|Vyfat 120mg Capsule (Intas Pharmaceuticals Ltd.)||$ 0.83|
|WONLISTAT tab 60 mg x 10's (Wonder (Xtra))|
|WONLISTAT tab 120 mg x 10's (Wonder (Xtra))|
|Xenical (Argentina, Armenia, Aruba, Australia, Austria, Bangladesh, Belarus, Belgium, Bolivia, Bosnia & Herzegowina, Botswana, Brazil, Brunei Darussalam, Cambodia, Canada, Chile, China, Colombia, Croatia (Hrvatska), Cuba, Cyprus, Czech Republic, Denmark, Ecuador, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Hong Kong, Hungary, Iceland, Indonesia, Ireland, Israel, Italy, Jamaica, Jordan, Kazakhstan, Kenya, Kuwait, Laos, Lebanon, Lithuania, Luxembourg, Macedonia, Malawi, Malaysia, Mexico, Morocco, Namibia, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Philippines, Poland, Portugal, Qatar, Romania, Russian Federation, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Sri Lanka, Sudan, Sweden, Switzerland, Taiwan, Tanzania, Thailand, Trinidad & Tobago, Turkey, Turkmenistan, Uganda, Ukraine, United Arab Emirates, United Kingdom, United States, Uruguay, Uzbekistan, Venezuela, Vietnam, Zambia, Zimbabwe)|
|Capsule; Oral; Orlistat 120 mg (USV-Corvette (US Vitamins Ltd))|
|Generic Xenical 120mg - 42 Capsule (USV-Corvette (US Vitamins Ltd))||$ 114.95|
|Generic Xenical 120mg - 84 Capsule (USV-Corvette (US Vitamins Ltd))||$ 199.95|
|Xenical 120 mg - 21 Tablets (USV-Corvette (US Vitamins Ltd))||$ 57.20|
|Xenical 120 mg x 4 x 21's (USV-Corvette (US Vitamins Ltd))|
|Xenical 120 mg x 21's (USV-Corvette (US Vitamins Ltd))||$ 22.81|
|Xenical 120 mg x 84's (USV-Corvette (US Vitamins Ltd))|
|Xenical 120 mg x 21 Tablet (USV-Corvette (US Vitamins Ltd))|
|Xenical 120 mg x 42's (USV-Corvette (US Vitamins Ltd))|
|Xenical 120 mg x 4 Blister x 21 Tablet (USV-Corvette (US Vitamins Ltd))|
|Xenical 120 mg Capsule (USV-Corvette (US Vitamins Ltd))||$ 0.83|
|XENICAL 120 MG CAPSULE 1 strip / 21 capsules each (USV-Corvette (US Vitamins Ltd))||$ 17.59|
|XENICAL cap 120 mg x 10's (USV-Corvette (US Vitamins Ltd))||$ 7.62|
- DailyMed. "ORLISTAT: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "orlistat". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "orlistat". http://www.drugbank.ca/drugs/DB01083 (accessed September 17, 2018).
- Wikipedia. "orlistat: Link to the compound information in Wikipedia.". https://en.wikipedia.org/wiki/Orlist... (accessed September 17, 2018).
- MeSH. "Anti-Obesity Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
ReviewsThe results of a survey conducted on ndrugs.com for Slimfast are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Slimfast. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
3 consumers reported usefulWas the Slimfast drug useful in terms of decreasing the symptom or the disease?
According to the reports released by ndrugs.com website users, the below mentioned percentages of users say the drug is useful / not useful to them in decreasing their symptoms/disease. The usefulness of the drug depends on many factors, like severity of the disease, perception of symptom, or disease by the patient, brand name used [matters only to a certain extent], other associated conditions of the patient. If the drug is not effective or useful in your case, you need to meet the doctor to get re-evaluated about your symptoms/disease, and he will prescribe an alternative drug.
4 consumers reported price estimatesWas the price you paid to purchase the drug reasonable? Did you feel it was expensive?
The below mentioned numbers have been reported by ndrugs.com website users about whether the Slimfast drug is expensive or inexpensive. There is a mixed opinion among users. The rating about the cost of the drug depends on factors like which brand drug the patient purchased, how effective it was for the price paid, the country or place the drug is marketed, and the economic condition of the patient. The users who feel the drug is expensive can look for an alternative brand drug or a generic drug to save the cost.
13 consumers reported time for resultsTo what extent do I have to use Slimfast before I begin to see changes in my health conditions?
As part of the reports released by ndrugs.com website users, it takes 1 day and a few days before you notice an improvement in your health conditions.
Please note, it doesn't mean you will start to notice such health improvement in the same time frame as other users. There are many factors to consider, and we implore you to visit your doctor to know how long before you can see improvements in your health while taking Slimfast. To get the time effectiveness of using Slimfast drug by other patients, please click here.
21 consumers reported age
There are no reviews yet. Be the first to write one!
Information checked by Dr. Sachin Kumar, MD Pharmacology